Quarterly report pursuant to Section 13 or 15(d)

Collaboration and Research Arrangements - Additional Information (Details)

v3.24.2
Collaboration and Research Arrangements - Additional Information (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Revenue recognized   $ 2,833,000   $ 5,787,000
Global Blood Therapeutics | Collaboration Agreement        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Deferred revenue, short-term   2,200,000   2,200,000
Revenue recognized $ 0 $ 2,800,000 $ 0 $ 5,800,000